European Commission grants marketing approval for Nezglyal (leriglitazone) for pediatric male cALD

Approval granted under exceptional circumstances for NEZGLYAL (leriglitazone) to treat pediatric male cALD. Neuraxpharm will commercialize in Europe under license from Minoryx Therapeutics; first launch expected in Germany by end-2026 for ages 2-12 with gadolinium-negative brain lesions.